Use of amantadine in the evaluation of response to chemotherapy in lung cancer: a pilot study

Author:

Maksymiuk Andrew W12,Tappia Paramjit S3ORCID,Bux Rashid Ahmed4,Moyer Dante4,Huang Guoyu4,Joubert Philippe5ORCID,Miller Donald W6,Ramjiawan Bram36,Sitar Daniel S26

Affiliation:

1. Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada

2. Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3A 1R9, Canada

3. Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, MB, R2H 2A6, Canada

4. BioMark Diagnostics Inc., Richmond, BC, V6X 2W2, Canada

5. Department of Pathology, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec, PQ, G1V 4G5, Canada

6. Department of Pharmacology & Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3E 0T6, Canada

Abstract

Aim: The assessment of tumor response to therapy is of critical importance as it permits for a prospective end point evaluation and provides a guide to clinicians for making future treatment decisions. However, current practices in early evaluation of chemotherapy are insufficient. Amantadine is a substrate for SSAT-1. The present pilot study tests the hypothesis that SSAT-1 activity within the tumor, as measured by plasma acetylamantadine concentrations, can be used to monitor patient response to therapy. Results: In cases with evidence of disease response, there was a reduction in the plasma acetylamantadine concentration at 4 h by approximately 32%. There was a mean increase of approximately 34% at the 4 h collection in the nonresponders. Conclusion: Although large-scale studies are required these findings suggest that the amantadine test could allow for determination of the efficacy of therapeutic interventions earlier, providing an effective test to assess response to treatment and for better management of patients.

Funder

Biomark Technologies Inc.

Maunders-McNeil Foundation

University of Manitoba

Publisher

Future Science Ltd

Subject

Biotechnology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3